# CALIBRA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/calibra

- Industry: Healthcare
- Headquarters: Hangzhou, China
- Website: www.calibradx.com
- Total disclosed funding: $62M
- Latest round: Series C (May 5, 2022)
- Investors on record: 9

## About

Established in 2016 and based in Hangzhou, China, CALIBRA is a high-tech company that engages in researching and developing, clinical transformation and application of a new generation of biomarker material spectrum detection technology. Liu Huafen, the CEO of the company, was the global director of SCIEXLabs, the application innovation platform of the Danaher Group SCIEX. The company has more than ten ultra-high resolution and quantitative mass spectrometers for the analysis of complex matrix samples, as well as Hamilton Microlab STAR M high-throughput automated pipetting workstations and other pre-processing systems.

The services provided by the company include clinical research and health management, metabolomics, Pharma CRO and environmental/toxicology. The products provided by the company include vitamin series, bile acid series, drug concentration series and other supporting reagents; chromatographic columns, pre-treatment plates, 96 microplates, 96SLE plates and other experimental consumables.

The company will focus on the research and development and registration of innovative instruments and reagents, and will accelerate the layout of our national marketing network and the expansion of our product capacity.

## Funding rounds

- Series C, May 5, 2022, $33M — China International Capital Corporation, CICC Pucheng Investment, Hangzhou Xihu District Science and Technology Equity Investment, Fosun Health Capital, Qishen Venture Capital
- Series B, Jan 8, 2021, $23M — Green Pine Capital Partners, Hillhouse Investment, GL Capital Group
- Series A, Feb 27, 2020, $6M — BioTrack Capital

## Investors

- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B
- GL Capital Group (https://capitalatlas.ai/funds/gl-capital-group) — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series C
- CICC Pucheng Investment — Series C
- Hangzhou Xihu District Science and Technology Equity Investment — Series C
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series C
- Qishen Venture Capital — Series C